Please provide your email address to receive an email when new articles are posted on . A majority of patients with age-related macular degeneration treated with investigational gene therapy GT005 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...
Hosted on MSN
Research reveals rare form of neuroinflammatory disease is more common in Old Order Amish than general population
Researchers from Children's Hospital of Philadelphia (CHOP) and the Clinic for Special Children found that complement factor I (CFI) deficiency, an ultra-rare genetic disorder that can cause ...
Please provide your email address to receive an email when new articles are posted on . In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results